Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib
- 26 December 2016
- journal article
- research article
- Published by Elsevier in European Journal of Radiology
- Vol. 88, 15-20
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Image-guided radiotherapy platform using single nodule conditional lung cancer mouse modelsNature Communications, 2014
- Volumetric tumor growth in advanced non‐small cell lung cancer patients with EGFR mutations during EGFR‐tyrosine kinase inhibitor therapyCancer, 2013
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyThe Lancet Oncology, 2012
- Reactivation of ERK Signaling Causes Resistance to EGFR Kinase InhibitorsCancer Discovery, 2012
- Measurement of Tumor Volumes Improves RECIST-Based Response Assessments in Advanced Lung CancerTranslational Oncology, 2012
- CT Tumor Volume Measurement in Advanced Non-small-cell Lung CancerAcademic Radiology, 2011
- Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion OncogeneCancer Research, 2010
- Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidenceAnnals of Oncology, 2010
- The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapiesCancer Cell, 2006
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000